Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-014-3126-0.pdf
Reference31 articles.
1. Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of dual kinase inhibitor lapatinib against HER-2 overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630–1639
2. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261–269
3. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743
4. Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543
5. Bachelot T, Romieu G, Campone M et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer: a single-group phase 2 study. Lancet Oncol 14:64–71
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An Exploration of Students' Anxiety in Mathematics Online Learning using Augmented Reality at Junior High School: A Rasch Model Construct;PEGEM EGIT OGR DERG;2024
2. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database;Drugs - Real World Outcomes;2021-09-15
3. Impact of ErbB receptors and anticancer drugs against breast cancer: A review;Current Pharmaceutical Biotechnology;2021-07-19
4. Prescribing patterns in breast cancer survivors: A Korean National Health Insurance Service cohort study;Int. Journal of Clinical Pharmacology and Therapeutics;2021-05-01
5. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice;Supportive Care in Cancer;2021-01-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3